- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT03049397
Enhancing Connections Program in Improving Family Adjustment in Patients With Incurable Cancer
Family Functioning and Bereavement Outcomes Following the Enhancing Connections Program in Palliative Care
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Yksityiskohtainen kuvaus
PRIMARY OBJECTIVES:
I. Test the feasibility of the study protocol in advanced cancer patients and co-parents (recruitment/retention, dosage and fidelity of the intervention; program acceptability of program; and logistics).
II. Evaluate the short-term impact of the program on the diagnosed parents', co-parents' and children's adjustment and family functioning using a within group design (pre- and posttest design).
III. Compare outcomes from the Enhancing Connections Palliative Program with similar outcomes obtained from the completed phase III trial (between group design) for the patients and children outcomes.
IV. Evaluate the longer term impact of the program on the co-parents' and children's adjustment, including bereavement outcomes when appropriate, using a within and across group design (pre- and posttest design).
OUTLINE:
Patients and co-parents participate in the Enhancing Connections program consisting of 5 sessions over 1 hour each in the clinic or over the telephone. Session topics include managing cancer-related emotions when talking to children, developing deep listening skills, initiating difficult cancer-related conversations with children, interpreting a child's behavior, recognizing newly acquired gains from the program, and identifying available resources that can be used after program completion.
After completion of the study, participants are followed-up at 6 months.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Washington
-
Seattle, Washington, Yhdysvallat, 98109
- Fred Hutch/University of Washington Cancer Consortium
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
PATIENTS
- Ages 25-65 years
- Have a diagnosis of incurable cancer of any type; at any time in the diagnosis as long as they have at least a 4 month life expectancy based on the opinion of the attending physician
- Read and write English among their languages of choice
- Parent must live at least 50% of the time in the home and have a child 5-17 years old living at home who has been told their parent's cancer diagnosis
CO-PARENTS
- Co-parents must reside with the consenting eligible cancer participant (and child) at least 50% of the time and be actively participating in the care of the child
- If a biological parent lives in the home, and is physically well themselves, this person must be the co-parent
- If a biological parent does not live in the home (or has died), the co-parent does not have to be a biological parent; therefore, co-parents may be step-parents, lesbian, gay, bi-sexual or transgender (LGBT) partners, grandparents, aunts, uncles, etc if they otherwise meet eligibility criteria
- He or she can read and write English among their languages of choice and agrees to attend the patient intervention sessions in person or by telephone
CHILDREN
- The patient and co-parent must agree to focus on the same child throughout the study and consent to have the child participate before the child's assent will be sought
- Children aged 5-13 years of age will participate with a waiver of assent
- Children aged 14-17 will assent to participate in the research study by signing a separate assent form
- Children of formal assenting age will be eligible to participate if they can read and write English among their languages of choice
ALL PARTICIPANTS
- Participants must live within 35 miles of the University of Washington, Seattle, WA to receive the in-person version of the intervention
- Parents and co-parents selecting the telephone version of the intervention may live any distance from the University of Washington
Exclusion Criteria:
- Patients will be excluded if they are enrolled in hospice at time of enrollment; however, they will be allowed to continue in the study if they enroll in hospice after beginning the study
- The triad will be ineligible if any member lives in the home less than 50% of the time
- If any member of the triad retracts consent or assent prior to completion of the post-intervention surveys, then all members will be excluded from the study thereafter
- The child will be excluded if he or she has learning challenges as assessed by the patient or co-parent; patients and co-parents will be instructed to consider any formal diagnoses of a learning disability of the presence of an Individual Education Plan (IEP) when making this assessment
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Tukevaa hoitoa
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Supportive Care (Enhancing Connections program)
Patients and co-parents participate in the Enhancing Connections program consisting of 5 sessions over 1 hour each in the clinic or over the telephone.
Session topics include managing cancer-related emotions when talking to children, developing deep listening skills, initiating difficult cancer-related conversations with children, interpreting a child's behavior, recognizing newly acquired gains from the program, and identifying available resources that can be used after program completion.
|
Apututkimukset
Complete Enhancing Connections program
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Feasibility of the Enhancing Connections program in advanced cancer patients and co-parents
Aikaikkuna: Up to 2 years
|
Recruitment and retention of all triads will be monitored.
Dosage and fidelity will be monitored for each intervention session.
Program acceptability (per session, overall, duration of program, interval between intervention sessions) will be assessed from a debriefing interview.
For logistics four areas will be monitored: rate of receipt of mailed materials both to participants and from participants; duration and type (whether telephone or in-person) of intervention sessions; rate of success in scheduling and completing intervention sessions with patient and co-parent; and quality of data on baseline, post-intervention and follow-up measures.
|
Up to 2 years
|
|
Change in adjustment and family functioning
Aikaikkuna: Baseline to 6 months
|
Descriptive statistics (e.g.
means, medians) will be used to describe the Enhancing Connections palliative care population.
Parents', co-parents and children's baseline scores [parent-reported] on standardized questionnaires will be compared with post-intervention and 6 month follow-up scores on the same measures.
|
Baseline to 6 months
|
|
Outcomes from the Enhancing Connections Palliative Program as measured by the Child Behavior Check List
Aikaikkuna: Up to 2 years
|
Linear mixed modeling based on Maximum Likelihood Estimation will be used to test the differences between the Child Behavior Check List results for the Enhancing Connections Palliative Program and the completed phase III trial (EC-R01).
|
Up to 2 years
|
|
Change in adjustment as measured by post-traumatic growth scores
Aikaikkuna: Baseline to 6 months
|
Enhancing Connection Palliative Program parents', co-parents' and children's post-traumatic growth scores will be compared with follow-up (6 month) scores on the same measure.
|
Baseline to 6 months
|
Yhteistyökumppanit ja tutkijat
Sponsori
Yhteistyökumppanit
Tutkijat
- Päätutkija: Elizabeth Loggers, Fred Hutch/University of Washington Cancer Consortium
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- 9667 (Muu tunniste: Fred Hutch/University of Washington Cancer Consortium)
- P30CA015704 (Yhdysvaltain NIH-apuraha/sopimus)
- NCI-2016-01640 (Rekisterin tunniste: CTRP (Clinical Trial Reporting Program))
- RG9218011 (Muu tunniste: Fred Hutch/University of Washington Cancer Consortium)
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Pitkälle edennyt pahanlaatuinen kasvain
-
Gaziantep Islam Science and Technology UniversityEi vielä rekrytointia
-
Millennium Pharmaceuticals, Inc.Valmis
-
West China HospitalRekrytointiPMMR/MSS Advanced ColorektaalisyöpäKiina
-
Yale UniversityNational Institute of Nursing Research (NINR)Valmis
-
Novartis PharmaceuticalsValmiscMET Dysegulation Advanced Solid TumorsItävalta, Tanska, Ruotsi, Yhdistynyt kuningaskunta, Espanja, Saksa, Alankomaat, Yhdysvallat
-
Novartis PharmaceuticalsValmiscMET-dysregulated Advanced Solid TumorsYhdysvallat, Espanja, Italia, Bulgaria, Yhdistynyt kuningaskunta, Ranska, Tanska
-
Shanghai Qilu Pharmaceutical Research and Development...Ei vielä rekrytointia
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdRekrytointiKRAS G12C Mutant Advanced Solid TumorsKiina
-
AmgenAktiivinen, ei rekrytointiKRAS p.G12C Mutant Advanced Solid TumorsYhdysvallat, Ranska, Kanada, Espanja, Belgia, Itävalta, Australia, Unkari, Kreikka, Japani, Brasilia, Saksa, Sveitsi, Portugali, Romania, Etelä -Korea